Stoke Therapeutics (NASDAQ:STOK) Trading Down 5% - What's Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s share price fell 5% during mid-day trading on Wednesday . The stock traded as low as $11.35 and last traded at $11.50. 82,661 shares were traded during trading, a decline of 89% from the average session volume of 739,745 shares. The stock had previously closed at $12.10.

Wall Street Analysts Forecast Growth

A number of research firms have commented on STOK. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partners initiated coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an "outperform" rating and a $18.00 price target on the stock. Leerink Partnrs raised Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $20.83.

Stoke Therapeutics Price Performance

The stock has a market capitalization of $588.46 million, a P/E ratio of -5.29 and a beta of 0.95. The stock has a 50 day moving average price of $12.51 and a 200-day moving average price of $13.61.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. The company had revenue of $4.89 million during the quarter, compared to analysts' expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Research analysts predict that Stoke Therapeutics, Inc. will post -2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total value of $88,150.14. Following the completion of the sale, the chief executive officer now directly owns 61,885 shares in the company, valued at $803,886.15. This trade represents a 9.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Barry Ticho sold 10,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the transaction, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,000,349 shares of company stock valued at $28,031,296 over the last ninety days. 11.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lynx1 Capital Management LP raised its stake in Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock worth $70,052,000 after acquiring an additional 1,488,371 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Stoke Therapeutics by 426.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock worth $18,741,000 after purchasing an additional 1,123,500 shares in the last quarter. Logos Global Management LP purchased a new stake in shares of Stoke Therapeutics in the 2nd quarter valued at about $14,186,000. Marshall Wace LLP boosted its holdings in shares of Stoke Therapeutics by 550.1% in the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company's stock valued at $15,686,000 after acquiring an additional 982,451 shares during the period. Finally, RTW Investments LP grew its position in shares of Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after acquiring an additional 427,447 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.